MSD launches rotavirus vaccine

March 10, 2011 12:46 am | Updated 12:46 am IST - NEW DELHI:

LIFE SAVING: MSD Managing Director K. G. Ananthakrishnan (left) and Merck & Co Vice-President Ramesh Subramanian, at the launch of RotaTeq vaccine in New Delhi on Wednesday. Photo: R. V. Moorthy

LIFE SAVING: MSD Managing Director K. G. Ananthakrishnan (left) and Merck & Co Vice-President Ramesh Subramanian, at the launch of RotaTeq vaccine in New Delhi on Wednesday. Photo: R. V. Moorthy

Multinational pharmaceutical drug company MSD, the fully owned subsidiary of Merck & Co, on Wednesday launched a diarrhoea-prevention vaccine RotaTeq for infants and children in India.

RotaTeq is a pentavalent rotavirus vaccine that helps in preventing rotavirus gastroenteritis, a leading cause of severe and life threatening diarrhoea in young children.

Rotavirus is associated with 39.2 per cent of all diarrhoea-related hospital admissions in India among children aged less than five years. According to estimates, nearly six lakh children die of rotavirus each year globally.

“We are launching the vaccine at Rs.900 a dose for private market in the country,'' MSD Managing Director in India K. G. Ananthakrishnan told reporters here.

While the first dosage of the oral three dose RotaTeq vaccine could be administered between six and twelve weeks of age, the subsequent doses need to be given at a minimal interval of four weeks between each dosage. It can be given up to the age of six years. The company will produce the vaccine in the U.S. and then import and market it in India.

“India suffers from a high disease burden of rotavirus associated diarrhoea which also leads to high child mortality in the country. As a part of our commitment to address the unmet medical needs in the country, MSD has launched RotaTeq in India,'' Mr. Ananthakrishnan said.

RotaTeq is a pentavalent rotavirus vaccine specifically designed to help protect against common rotavirus serotypes that cause more than 90 per cent of rotavirus disease worldwide (G1, G2, G3, G4 serotypes) 5. The safety profile and efficacy of RotaTeq was established in Phase III studies on more than 71,000 infants, including the landmark Rotavirus Efficacy and Safety Trial (REST), one of the largest pre-licensure vaccine clinical trials conducted

Meanwhile, MSD Pharmaceuticals has formed a 50:50 joint venture — Hilleman Laboratories — with U.K.-based Wellcome Trust to develop a heat resistant rotavirus diarrhoea vaccine in India. In India, MSD operates through three separate legal entities — MSD Pharmaceuticals, Organon India and Fulford India.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.